基于组蛋白去乙酰化酶6设计的抗肿瘤抑制剂研究进展
Research progress in antitumor inhibitors based on histone deacetylase 6
谢昭 1王瑞 1陈瀚 1王岩石1
作者信息
- 1. 朴创医药科技(天津)有限公司,天津 300301;天津药物研究院药物成药性评价与系统性转化全国重点实验室,天津 300301;天津药物研究院天津市新药设计与发现重点实验室,天津 300301
- 折叠
摘要
组蛋白去乙酰化酶6(HDAC6)是组蛋白去乙酰化酶家族成员,除了可以调控组蛋白的乙酰化状态外,还能催化多种非组蛋白底物,如α-tubulin、cortactin、HSP90、HSF-1、Ku-70和PD-L1等,这些非组蛋白底物在肿瘤的发生发展过程中起到重要作用,因此,HDAC6已成为抗肿瘤药物研发的潜在靶点.本文作者对近年来HDAC6抑制剂的研究进展进行综述,并根据化合物结构进行归纳和总结,以期为后续研究提供思路与方向.
Abstract
Histone deacetylase 6(HDAC6)is a member of the histone deacetylase family,which not only regulates the acetylation state of histones,but also catalyzes various nonhistone substrates,includingα-tubulin,cortactin,HSP90,HSF-1,Ku-70,and PD-L1.These substrates play important roles in the occurrence and development of tumors.Therefore,HDAC6 has become a potential target for the development of antitumor drugs.In this paper,the research progress in antitumor inhibitors based on histone deacetylase 6 was introduced,and the compounds on the basis of structure in recent years were summarized.This review will provide ideas and directions for the further research.
关键词
组蛋白去乙酰化酶6/小分子抑制剂/抗肿瘤药物Key words
histone deacetylase 6/small molecule inhibitor/antitumor drug引用本文复制引用
出版年
2024
NETL
NSTL
万方数据